We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Genzyme Corp. - Genzyme Corp. Common Stock (MM) | NASDAQ:GENZ | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 76.25 | 0 | 01:00:00 |
Sanofi-Aventis (SNY) unit Genzyme will present results of phase II trials of its alemtuzumab multiple sclerosis treatment at an American Academy of Neurology meeting in Hawaii April 9 through April 16.
MAIN FACTS:
- The company will present additional Phase 2 trial safety and efficacy data on the clinically-active disease status of patients through five-years of patient follow-up as well as data describing a measure of vision improvement at the meeting.
-"We look forward to the availability of Phase 3 results in the middle of this
year," said Michael Panzara, Genzyme Group Vice President and Therapeutic Area Head for Multiple Sclerosis and Immune Diseases.
- Genzyme is currently conducting two pivotal Phase 3 trials to evaluate alemtuzumab in the treatment of MS.
- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; mimosa.spencer@dowjones.com
1 Year Genzyme Chart |
1 Month Genzyme Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions